

UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MASSACHUSETTS

JOHN HANCOCK LIFE INSURANCE
COMPANY, JOHN HANCOCK
VARIABLE LIFE INSURANCE
COMPANY and MANULIFE
INSURANCE COMPANY,

Plaintiffs,

v.

ABBOTT LABORATORIES,

Defendant.

CIVIL ACTION NO. 05-11150-DPW

ABBOTT'S DEPOSITION DESIGNATIONS AND COUNTER DESIGNATIONS
FOR JEANNE M. FOX

Defendant Abbott Laboratories ("Abbott") respectfully submits the attached deposition designations and counter-designation for the May 17, 2007 deposition of Jeanne M. Fox, Divisional Vice President of the North American Regulatory Affairs

Dated: February 18, 2008

Respectfully submitted,

ABBOTT LABORATORIES

By: /s/ Eric J. Lorenzini
Eric J. Lorenzini

Jeffrey I. Weinberger (*pro hac vice*)
Gregory D. Phillips (*pro hac vice*)
Eric J. Lorenzini (*pro hac vice*)
Ozge Guzelsu (*pro hac vice*)
MUNGER, TOLLES & OLSON LLP
355 South Grand Avenue, Thirty-Fifth
Floor
Los Angeles, CA 90071-1560
Tele: (213) 683-9100

and

Peter E. Gelhaar (BBO#188310)
Michael S. D'Orsi (BBO #566960)
DONNELLY, CONROY &
GELHAAR LLP
1 Beacon St., 33rd Floor
Boston, Massachusetts 02108
(617) 720-2880
peg@dcglaw.com
msd@dcglaw.com

Counsel for Abbott Laboratories

CERTIFICATE OF SERVICE

I hereby certify that this document(s) filed through the ECF system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing (NEF) and paper copies will be sent to those indicated as non registered participants on February 18, 2008.

Date: February 18, 2008.

_____/s/ Ozge Guzelsu

Jeanne Fox Deposition Designations

Depo Date	Witness	Hancock Designation	Abbott Counter Designation	Abbott Designation	Deposition Exhibit	Plaintiff Exhibit	Defendant Exhibit
05/17/07	Fox, Jeanne	5:5-5:19					
05/17/07	Fox, Jeanne	25:19-27:7			2	HZ	
05/17/07	Fox, Jeanne	40:10-41:3					
05/17/07	Fox, Jeanne	45:17-46:4					
05/17/07	Fox, Jeanne	46:24-47:10			3	ID	
05/17/07	Fox, Jeanne	48:1-48:8			3	ID	
05/17/07	Fox, Jeanne	49:10-49:18			3	ID	
05/17/07	Fox, Jeanne	51:3-51:6			3	ID	
05/17/07	Fox, Jeanne	55:19-57:15			4	IG	
05/17/07	Fox, Jeanne	57:22-58:8			4	IG	
05/17/07	Fox, Jeanne	60:15-60:17			5	IE	
05/17/07	Fox, Jeanne	61:11-62:22			4	IG	
05/17/07	Fox, Jeanne	74:18-75:3					
05/17/07	Fox, Jeanne	77:2-77:18					
05/17/07	Fox, Jeanne	78:9-78:22			4	IG	
05/17/07	Fox, Jeanne	82:12-82:20			4	IG	
05/17/07	Fox, Jeanne	95:15-96:2			6	IF	
05/17/07	Fox, Jeanne	114:23-115:24			8	IO	
05/17/07	Fox, Jeanne	116:24-117:14					
05/17/07	Fox, Jeanne	129:6-129:16			10	IQ	
05/17/07	Fox, Jeanne	131:3-131:17			10	IQ	
05/17/07	Fox, Jeanne	133:22-134:20			10	IQ	

Depo Date	Witness	Hancock Designation	Abbott Counter Designation	Abbott Designation	Deposition Exhibit	Plaintiff Exhibit	Defendant Exhibit
05/17/07	Fox, Jeanne	136:11- 137:17			10	IQ	
05/17/07	Fox, Jeanne	138:1-138:6			10	IQ	

Color Key to Deposition Designations

 **Designation by Plaintiffs**

 **Counter Designation by Defendants**

 **Designation by Defendants**

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 UNITED STATES DISTRICT COURT
2 FOR THE DISTRICT OF MASSACHUSETTS

3
4 JOHN HANCOCK LIFE INSURANCE)
5 COMPANY, JOHN HANCOCK VARIABLE)
6 LIFE INSURANCE COMPANY and)
7 MANULIFE INSURANCE COMPANY)
8 (f/k/a INVESTORS PARTNER)
9 INSURANCE COMPANY),)

10 Plaintiffs,) Civil Action No.

11 -vs-) 05-11150-DPW

12 ABBOTT LABORATORIES,)

13 Defendant.)

14

15

16

17 C O N F I D E N T I A L

18

19 THE VIDEOTAPED DEPOSITION OF

20 JEANNE FOX

21

22 May 17, 2007

23

24

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

The videotaped deposition of JEANNE FOX,
called by the Plaintiffs for examination, taken
pursuant to the Federal Rules of Civil Procedure of
the United States District Courts pertaining to the
taking of depositions, taken before CORINNE T.
MARUT, C.S.R. No. 84-1968, a Notary Public within
and for the County of DuPage, State of Illinois,
and a Certified Shorthand Reporter of said state,
at the offices of Levenfeld & Pearlstein LLC, Suite
1300, Two North LaSalle Street, Chicago, Illinois,
on the 17th day of May, A.D. 2007, commencing at
9:10 a.m.

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 PRESENT:

2 CHOATE, HALL & STEWART LLP,

3 (Two International Place,

4 Boston, Massachusetts 02110,

5 617-248-5000), by:

6 MR. JOSEPH H. ZWICKER,

7 jzwicker@choate.com,

8 appeared on behalf of the Plaintiffs;

9

10 MUNGER, TOLLES & OLSON LLP,

11 (355 South Grand Avenue, 35th Floor,

12 Los Angeles, California 90071-1560,

13 213-683-9276), by:

14 MR. GREGORY D. PHILLIPS,

15 gregory.phillips@mto.com,

16 appeared on behalf of the Defendant

17 and the Deponent.

18

19 VIDEOTAPED BY:

20 WES FRANCE,

21 Esquire Deposition Services.

22

23

24 REPORTED BY: CORINNE T. MARUT, C.S.R. No. 84-1968

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 THE VIDEOGRAPHER: Good morning. We are going
2 on the video record at 9:10 a.m.

3 My name is Wes France and I'm a legal
4 videographer in association with Esquire Deposition
5 Services. Our address is 311 West Monroe Street,
6 Chicago, Illinois. The Court Reporter today is
7 Corey Marut of Esquire Deposition Services.

8 Here begins the videotaped deposition of
9 Jeanne Fox, taking place at 2 North LaSalle Street,
10 Chicago, Illinois.

11 Today's date is May 17, 2007.

12 This deposition is being taken in the
13 matter of John Hancock Life Insurance Company,
14 et al. vs. Abbott Laboratories, in the United
15 States District Court for the District of
16 Massachusetts, Case No. 05-11150-DPW.

17 Will counsel please state their names
18 for the record.

19 MR. ZWICKER: Joseph Zwicker, Choate, Hall &
20 Stewart, for the Plaintiffs.

21 MR. PHILLIPS: Greg Phillips, Munger, Tolles &
22 Olson, for Abbott Laboratories, Defendant, and for
23 the witness.

24 THE VIDEOGRAPHER: Will the reporter now swear

1 in the witness, please.

2 (WHEREUPON, the witness was duly

3 sworn.)

4 MR. ZWICKER: Ready?

5 JEANNE FOX,

6 called as a witness herein, having been first duly

7 sworn, was examined and testified as follows:

8 EXAMINATION

9 BY MR. ZWICKER:

10 Q. Good morning, Ms. Fox.

11 A. Good morning.

12 Q. Is it Ms. or Dr. or something else?

13 A. Ms. is fine.

14 Q. Ms. is fine. Where do you work?

15 A. I work at Abbott Laboratories.

16 Q. What's your job there?

17 A. I'm the senior director in global

18 pharmaceutical regulatory affairs, heading up the

19 U.S. regulatory affairs area.

20 Q. How long have you had that position?

21 A. I've been direct -- senior director of

22 U.S. regulatory affairs since January of 2004.

23 Q. What are your responsibilities as global

24 pharmaceutical regulatory affairs director?

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 that point in time. So, there might have been
2 someone else who made a specific filing if I needed
3 the assistance.

4 BY MR. ZWICKER:

5 Q. Who was on your staff?

6 A. Matt Biondi I believe was with me during
7 that time frame. Alexa Chun was with me during
8 that time frame. Rebecca Welch worked for me.
9 Greg Bosco.

10 Q. What did Greg Bosco do with respect to
11 773?

12 A. With respect to 773, he made a number of
13 the submissions to the IND.

14 Q. What else?

15 A. He would have prepared the regulatory
16 submissions. He would have been responsible for
17 seeing that the -- the actual clinical drug release
18 was done correctly within regulatory.

19 (WHEREUPON, a certain document was
20 marked Fox Deposition Exhibit
21 No. 2, for identification, as of
22 05-17-2007.)

23 MR. ZWICKER: Before the witness is Fox
24 Exhibit No. 2, which is an e-mail and covering

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 document dated September 13, 2000, and it bears

2 Bates Nos. ABBT 557552 through 557.

3 BY MR. ZWICKER:

4 Q. Ms. Fox, could you review Exhibit 2 and

5 let me know when you are done.

6 A. I'm finished.

7 Q. Do you recognize this document?

8 A. I don't remember it.

9 Q. Do you recognize the form of it?

10 A. Yes.

11 Q. What is it?

12 A. For a period of time we were asked to

13 prepare a section of a larger development plan for

14 compounds and the section was specific to

15 regulatory strategy and it had a prescribed format

16 to it.

17 Q. What role did you play in the

18 preparation of those documents?

19 A. They were prepared within the regulatory

20 group. So, either myself or someone working for me

21 would have drafted these in discussion with the

22 team.

23 Q. And you would have either written them

24 or reviewed them?

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 A. Correct.

2 Q. What would you review them for? What

3 was your purpose in reviewing them?

4 A. Regulatory accuracy.

5 Q. So, you wanted make sure that the

6 content of these documents was accurate. Fair?

7 A. From a regulatory perspective.

8 Q. What does that mean?

9 A. For instance, in Section D.3, the table

10 indicates what guidance documents were used to

11 assess what the requirements would be.

12 Q. Not your hunt?

13 A. Pardon?

14 Q. That's not your -- that's not what you

15 were looking to -- that's not what you were

16 focusing on, D.3, right?

17 Let me ask you a different question.

18 A. I don't understand the question.

19 Q. Look at D.1, "Regulatory Strategy SWOT

20 Analysis."

21 A. All right.

22 Q. You would have taken responsibility for

23 ensuring the accuracy of this portion of the

24 document, right?

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 testing to document that -- that a particular class
2 or a particular compound had absolutely no effect.
3 So, part of the challenge for us would
4 be to get FDA agreement on what it would take in
5 terms of how we would conduct the studies, whether
6 we would put EKG monitoring in the studies, how we
7 would do the assessment to satisfy their request to
8 see documentation that the product did not have the
9 potential to prolong QT.

10 Q. Abbott had the concern in -- as of
11 September 2000 that the FDA was scrutinizing QT
12 issues closely. Is that fair?

13 MR. PHILLIPS: Objection; lack of foundation
14 as to what Abbott thought or was concerned about.

15 BY THE WITNESS:

16 A. My recollection is that in the -- in the
17 regulatory arena at that time, FDA was very much
18 looking at QT prolongation as a -- as a new issue
19 that they would have to define how to study, how to
20 label.

21 BY MR. ZWICKER:

22 Q. And was your recollection that the FDA
23 hadn't provided very much guidance to drug
24 manufacturers about how it would consider the issue

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 and what it would require to get comfort that a
2 drug was safe?

3 A. That is my recollection.

4 Q. What is your understanding of what a
5 class issue is in connection with QTc prolongation
6 and as referred to in this document?

7 MR. PHILLIPS: Objection; vague, lack of
8 foundation.

9 BY THE WITNESS:

10 A. From a regulatory standpoint, when
11 something is considered a class issue, that
12 generally means FDA looks across a particular group
13 of compounds that are related either by structure
14 or by activity, and they look for that group of
15 compounds to behave similarly.

16 BY MR. ZWICKER:

17 Q. Was your recollection that the FDA --
18 well, strike that.

19 In your experience if the FDA looks
20 across a class of compounds to determine whether
21 they behave similarly, in your experience could
22 that have implications for delaying FDA approval in
23 bringing drugs to market?

24 MR. PHILLIPS: Objection; incomplete

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 Q. And NDA is New Drug Application?

2 A. That's correct.

3 MR. ZWICKER: Would you like a break?

4 THE WITNESS: No, I think I'm all right.

5 MR. ZWICKER: We have been going for a little
6 over an hour.

7 MR. PHILLIPS: Are you sure? Maybe we should
8 take a brief break, just stretch our legs.

9 THE VIDEOGRAPHER: We are going off the video
10 record at 10:11 a.m. This concludes Tape No. 1.

11 (WHEREUPON, a recess was had

12 from 10:11 to 10:22 a.m.)

13 THE VIDEOGRAPHER: We are going back on the
14 video record at 10:22 a.m. This is the beginning
15 of Tape No. 2.

16 BY MR. ZWICKER:

17 Q. Ms. Fox, do you recall attending or
18 participating in a teleconference with the FDA in
19 November of 2000 where the FDA put a halt on
20 Abbott's Phase III clinical trials for 773?

21 MR. PHILLIPS: Objection; assumes facts not in
22 the record.

23 BY THE WITNESS:

24 A. I recall that we had a teleconference

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 with FDA around the beginning of the Phase III
2 clinical trials. To my recollection, the FDA at
3 that point in time asked us to suspend enrollment
4 in the clinical trials.

5 BY MR. ZWICKER:

6 Q. Why did the FDA ask you to suspend
7 enrollment in the clinical trials?

8 MR. PHILLIPS: Well, objection; calls for
9 speculation.

10 You may answer if you understand the
11 question.

12 BY THE WITNESS:

13 A. I don't remember the details of the
14 discussion.

15 BY MR. ZWICKER:

16 Q. What was the purpose of that
17 teleconference, do you recall?

18 A. I don't remember if we asked for the
19 teleconference or they asked for it.

20 Q. You participated in it?

21 A. Yes.

22 MR. ZWICKER: Let's mark this as the next
23 exhibit.

24 (WHEREUPON, a certain document was

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 marked Fox Deposition Exhibit

2 No. 3, for identification, as of

3 05-17-2007.)

4 MR. ZWICKER: Before the witness is

5 Exhibit No. 3, which is an e-mail from Jeanne Fox

6 to various persons and a covering FDA contact

7 report.

8 BY MR. ZWICKER:

9 Q. Ms. Fox, could you review this document

10 and let me know when you're done.

11 MR. PHILLIPS: Counsel, just one question for

12 the record.

13 Do you know if the circle on the first

14 page is in the original document? I don't recall.

15 MR. ZWICKER: You know, Greg, I've come to

16 appreciate that level of meticulousness from you.

17 And, in fact, that -- that is my circle.

18 MR. PHILLIPS: Oh, okay. Thank you.

19 I will take it as a compliment. I'm not

20 sure it was intended as such.

21 MR. ZWICKER: It was intended as one.

22 BY MR. ZWICKER:

23 Q. Ready?

24 A. Yes.

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 Q. Ms. Fox, did you -- just looking at the
2 FDA contact report, which is -- ends in Bates
3 No. 682, did you write this FDA contact report?

4 A. It appears that I did.

5 Q. And do you believe that it was accurate
6 and complete when you wrote it?

7 A. My practice is to make them accurate and
8 complete.

9 Q. Did you submit it to anyone for review
10 who participated in the call?

11 A. I don't recall if I would have done that
12 or not.

13 Q. What was the purpose of your preparation
14 of this FDA contact report?

15 A. To communicate to my manager and to the
16 rest of the team what the outcome of the
17 teleconference was.

18 Q. I notice from the first page, which is
19 an e-mail from you to various persons, that you
20 sent it to John Leonard. Do you see that?

21 A. Yes, I see his name.

22 Q. Why did you send it to John Leonard?

23 A. I believe that it was sent to John
24 Leonard because the project team that we worked

1 with at that point in time would have reported in
2 to John Leonard.

3 Q. Does reviewing this document help you
4 recall that the subject of the November 20 contact
5 with the FDA related to toxicology issues?

6 A. That's what it states under "Subject of
7 Call."

8 Q. You remember that?

9 A. Yes.

10 Q. Do you remember that the FDA was
11 dissatisfied with Abbott's efforts regarding
12 toxicology studies and QTc and liver toxicity?

13 MR. PHILLIPS: Objection; vague.

14 BY THE WITNESS:

15 A. I recall that they were asking us to do
16 additional toxicology work and that they were
17 asking that based on information that they told us
18 they were not at liberty to share with us.

19 BY MR. ZWICKER:

20 Q. They were asking you to do additional
21 toxicology work based on information that they
22 couldn't share with you, is that what you're
23 saying?

24 A. Yes.

1 A. Yes, I believe that was my understanding
2 going into this telephone call.

3 Q. Is it fair to say that you were
4 surprised by the FDA's insistence on additional
5 toxicology work?

6 A. Yes.

7 Q. And did the FDA's request for additional
8 work cause you to believe that the FDA was taking
9 liver toxicity and QT issues very seriously?

10 A. I think it meant that they were -- they
11 were concerned enough about these two issues in
12 general that they wanted to make sure that we
13 specifically evaluated them in the way they were
14 recommending for this product.

15 Q. Were you surprised by their level of
16 concern?

17 A. I don't think that it is extremely
18 unusual that this kind of issue might arise during
19 development.

20 Q. Did you have any discussions with anyone
21 on the 773 team after the November 20th FDA
22 contact?

23 MR. PHILLIPS: I'm sorry. Objection; vague.
24 You mean about the contact?

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 follow that feedback, you are likely to -- to be
2 able to file an NDA without FDA changing their
3 position.

4 BY MR. ZWICKER:

5 Q. And an NDA is -- essentially marks
6 approval of the drug for commercialization?

7 A. It's the application that you submit to
8 get marketing approval.

9 Q. Did you in fact participate in the End
10 of Phase II meeting with the FDA?

11 A. Yes, I believe I did.

12 Q. Was that an in-person meeting or was it
13 a teleconference?

14 A. That was an in-person meeting.

15 Q. Do you recall who else participated with
16 you or attended with you?

17 A. I believe Carl Craft was in attendance.

18 I don't recall who else was there.

19 (WHEREUPON, a certain document was

20 marked Fox Deposition Exhibit

21 No. 4, for identification, as of

22 05-17-2007.)

23 MR. ZWICKER: Before the witness is Fox

24 Exhibit No. 4, which is an e-mail and a series of

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 covering slides.

2 BY MR. ZWICKER:

3 Q. Ms. Fox, if you wouldn't mind reviewing

4 this document and letting me know when you're done.

5 All done?

6 A. Yes.

7 Q. Just looking at the e-mail, it's an

8 e-mail authored by you, correct?

9 A. It appears to be.

10 Q. And is this your attempt to summarize

11 the significant events at the End of Phase II

12 meeting?

13 A. I can't tell that from this document.

14 It just looks like it's slides for an upcoming

15 meeting.

16 (WHEREUPON, a certain document was

17 marked Fox Deposition Exhibit

18 No. 5, for identification, as of

19 05-17-2007.)

20 MR. ZWICKER: Before the witness is Fox

21 Exhibit No. 5, which is an FDA contact report

22 bearing Bates Nos. 205257 through 259.

23 BY MR. ZWICKER:

24 Q. Ms. Fox, if you could look at that

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 contact report and let me know if it refreshes your
2 recollection regarding whether the slides that are
3 attached to this e-mail summarize the contact with
4 the FDA on November 27, 2000.

5 MR. PHILLIPS: Object to the form.

6 BY THE WITNESS:

7 A. Could you repeat the question?

8 BY MR. ZWICKER:

9 Q. Yes, of course.

10 Does reviewing Exhibit No. 5, which is
11 the FDA contact report, help you recall that the
12 Exhibit 4 and the accompanying slides are your
13 attempt to summarize the FDA contact on
14 November 27?

15 A. They appear to be.

16 Q. Let's just look at your e-mail for a
17 minute. You start by saying. "OK, here's my first
18 draft of slides for the Leiden meeting."

19 You prepared these slides by yourself or
20 with someone else's assistance?

21 A. I don't remember.

22 Q. And you believe that the slides you
23 prepared accurately reflect what took place at the
24 FDA contact on November 27, correct?

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 meeting with the FDA an important meeting in
2 connection with obtaining regulatory approval from
3 the FDA?

4 MR. PHILLIPS: Objection; vague.

5 BY THE WITNESS:

6 A. I think, as I said earlier, it's one of
7 the prescribed meetings that you're allowed to have
8 and it's a good way to get feedback so that when
9 you get ready to submit at the end of Phase III
10 you've done work that they recognize will satisfy
11 their requirements and will -- will hopefully allow
12 you to have the label that you're planning to have
13 at approval.

14 BY MR. ZWICKER:

15 Q. Take a look at Exhibit 5, which is the
16 FDA contact report. You wrote that, correct?

17 A. I believe so.

18 Q. Look at the Abbott representatives on
19 page 1.

20 A. Yes.

21 Q. And is this list consistent with your
22 practice that everyone on it attended the meeting
23 for Abbott?

24 A. Yes.

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 Q. You recall John Leonard being there?

2 A. No, I don't.

3 Q. Do you recall Carol Meyer being there?

4 A. No, I don't.

5 Q. What do you remember the discussion at
6 the November 27, 2000 contact involving regarding
7 QTc prolongation?

8 A. I don't remember the specifics of the
9 discussion. All I see is what's written here on
10 the page.

11 Q. Take a look at your slides and
12 specifically page 1, which is Bates numbered 818,
13 the last three digits anyway.

14 A. Okay.

15 MR. PHILLIPS: That's Exhibit 4, counsel, is
16 that right?

17 MR. ZWICKER: Yes.

18 BY MR. ZWICKER:

19 Q. The first bullet says, "ABT-773
20 Potential for QTc Prolongation."

21 Do you see that?

22 A. "QT Prolongation," yes.

23 Q. Yeah. It says, the next line does, "QT
24 issue is hot button for FDA."

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 Do you see that?

2 A. Yes.

3 Q. Are those your words or the FDA's?

4 A. Probably mine.

5 Q. Why did you choose them?

6 A. Because that's a slang way to represent
7 an issue that seems to be a topical issue for FDA.

8 So, in other words, it's prominent at the time.

9 It's important. You have to be aware of it. You
10 have to address it. Issues come and go with FDA.
11 They get resolved. If they're moving into a new
12 area.

13 As I said earlier, QT was one of those
14 issues that, when it started to become of interest
15 to FDA, then they had to assess how it should be
16 studied, what kind of direction they were going to
17 be giving to sponsors and ultimately what kind of
18 assessment would lead to what kind of label.

19 Q. You said that issues come and go with
20 the FDA. Would you agree that in November of 2000
21 QT prolongation was a hot button issue for the FDA?

22 A. It was a prominent issue right then.

23 Q. The next line down, you say, "Question
24 whether ketolides behave like macrolides."

1 A. I don't recall the discussion around
2 that issue.

3 BY MR. ZWICKER:

4 Q. The last bullet point says, "Plan to
5 conduct routine liver monitoring in all Phase III
6 studies."

7 Do you see that?

8 A. Yes.

9 Q. Do you recall whether or not Abbott's
10 decision to conduct routine liver monitoring in
11 Phase III studies came as a result of the FDA's
12 concern about liver toxicity?

13 A. No, I don't recall.

14 MR. PHILLIPS: I'm sorry. I wanted to
15 interpose an objection that the question assumes
16 facts not in the record.

17 BY MR. ZWICKER:

18 Q. What do you recall the discussion about
19 Abbott's intention to seek a resistance claim at
20 the November 27th meeting at the FDA?

21 A. I recall that they had not completely
22 defined what the burden of proof would be in terms
23 of the number of isolates. There was no written
24 guidance at that point in time. There was some

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 discussion around whether we could pool isolates
2 across different infectious diseases to reach a
3 higher total number.

4 Q. Did you feel that in some respects that
5 Abbott was in the dark with respect to what would
6 be required to achieve a resistance claim?

7 MR. PHILLIPS: Objection; vague.

8 BY THE WITNESS:

9 A. I don't think I would characterize that
10 as being Abbott being in the dark as much as FDA
11 not having made up its mind -- made up its mind
12 what would be considered adequate proof.

13 BY MR. ZWICKER:

14 Q. And if the FDA hadn't made up its mind
15 regarding what would be considered adequate proof,
16 then Abbott, you, would be uncertain whether or not
17 you could achieve a resistance claim, correct?

18 MR. PHILLIPS: Objection; vague as to what you
19 mean by "you."

20 BY THE WITNESS:

21 A. I think the purpose of the discussion at
22 the meeting was to try to propose something that
23 would get us -- get Abbott a claim for resistance
24 for ABT-773 and try to get FDA to concur what that

1 discussion.

2 Q. How about just for you. Were you
3 uncertain whether Abbott could achieve a resistance
4 claim after the November 27 meeting?

5 MR. PHILLIPS: Objection; vague.

6 BY THE WITNESS:

7 A. I think gaining the claim depended on
8 finding the isolates. I think we had a reasonable
9 discussion with FDA so that we had an idea of what
10 it would take.

11 But the -- the actual ability to achieve
12 that was completely dependent on our ability to
13 find patients with resistant organisms and to
14 successfully treat them.

15 BY MR. ZWICKER:

16 Q. And you didn't know whether you'd be
17 able to do that, right?

18 A. Correct.

19 MR. PHILLIPS: Objection; vague as to what you
20 mean by "you."

21 BY MR. ZWICKER:

22 Q. Take a look at Exhibit No. 4, the
23 page ending 821, the last three digits.

24 You write in the first bullet

1 point, "Indication to treat resistant pathogens."

2 Do you see that?

3 A. Yes.

4 Q. Was that your way of saying that Abbott
5 will be seeking an indication to seek resistant
6 pathogens?

7 A. I think it was a way of introducing the
8 topic of getting an indication.

9 Q. The next bullet point says, "FDA
10 skepticism regarding clinical significance of
11 'macrolide-resistant S.' pneumoniae or 'pneumo,'
12 which I assume is short for pneumonia.

13 What did you mean by that?

14 A. I recall the discussion around this
15 issue at the meeting was that FDA was uncertain of
16 what the actual clinical significance of
17 macrolide-resistant Strep pneumo was.

18 So, what that meant was it would be up
19 to us to provide enough data and documentation that
20 would actually provide proof that if someone had a
21 macrolide-resistant Strep pneumo that was a
22 pathogen that would -- that would cause harm.

23 MR. PHILLIPS: I'm sorry. Could you read back
24 that response, please.

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 that was discussed.

2 Q. Penicillin was the other?

3 A. Yes.

4 Q. You write in your slide that the FDA
5 was -- expressed skepticism regarding clinical
6 significance of macrolide-resistant *S. pneumoniae*.

7 Did you understand the FDA to be
8 skeptical regarding Abbott's ability to prove that
9 the problem existed, could be treated and that you
10 would be able to have efficacy with it?

11 Let me ask you a different question.

12 What do you mean when you say
13 "skepticism" in this line?

14 A. I believe that I would have used the
15 term to -- to ill' -- to describe that FDA had told
16 us that they weren't -- they didn't have data in
17 their hands at that point in time that said that
18 macrolide-resistant Strep pneumo is a clinical
19 concern. So, we would have to develop that data
20 for them.

21 Q. And speaking for yourself, were you
22 uncertain whether that could be done?

23 A. That wasn't my call to judge that.

24 Q. Did you have discussions with others

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 Q. Okay.

2 MR. ZWICKER: Do you want to change the tape?

3 THE VIDEOGRAPHER: We are going off the video

4 record at 11:39 a.m. This concludes Tape No. 2.

5 (WHEREUPON, a recess was had

6 from 11:39 to 11:51 a.m.)

7 THE VIDEOGRAPHER: We are going back on the

8 video record at 11:51 a.m. This is the beginning

9 of Tape No. 3.

10 (WHEREUPON, a certain document was

11 marked Fox Deposition Exhibit

12 No. 6, for identification, as of

13 05-17-2007.)

14 BY MR. ZWICKER:

15 Q. Ms. Fox, before you is Exhibit No. 6,

16 which is an e-mail from you to various persons

17 dated November 28, 2000.

18 Could you review it and let me know when

19 you're done.

20 A. Okay.

21 Q. Any reason to doubt that you wrote this

22 e-mail?

23 A. No.

24 Q. And having reviewed it, any doubts in

1 your mind about its accuracy?

2 A. No.

3 Q. You sent it to -- you cc'd Carol Meyer

4 on it. Do you see that? At the bottom. She's

5 right before Greg Bosco.

6 A. Yes.

7 Q. Why?

8 A. She worked on the project team at that

9 time. I don't remember the role that she had.

10 Q. Did you have a lot of contact with her?

11 A. Not that I remember.

12 Q. The very last sentence in the e-mail,

13 you say, "In addition, we were directed to modify"

14 all our -- "all of our informed consents to inform

15 patients that QT prolongation has been seen with

16 related classes of drugs and therefore may be a

17 risk with ABT-773."

18 Did you do that? Did Abbott do that?

19 Did it modify its consents?

20 MR. PHILLIPS: Objection; lack of foundation.

21 BY THE WITNESS:

22 A. I don't remember, but I presume we did.

23 BY MR. ZWICKER:

24 Q. Whose job would it have been to do that?

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 A. I don't recall any specifics.

2 Q. Do you recall generally that the FDA
3 expressed a concern at the conference about the
4 relationship between liver toxicity and
5 antibiotics?

6 A. I think this conference was not too long
7 after one of the major quinolones was removed from
8 the market, Trovan, and that was a product where
9 the company had developed a clinical safety
10 database of 10 to 11,000 patients prior to
11 approval.

12 So that the discussion was around the
13 size of that database and the, you know, the
14 inability to see even with that number of patients
15 a signal that would have predicted hepatotoxicity.

16 Q. What's a safety database?

17 A. It's the -- the term for the safety
18 assessment of all of the patients that you have in
19 your clinical trials. FDA calls that your safety
20 database.

21 Q. For all phases, 1, 2 and 3?

22 A. Yes.

23 Q. Did you come away from the meeting you
24 attended in Washington in 2001 with the

1 understanding that the FDA was carefully
2 scrutinizing liver toxicity issues in antibiotics
3 under development?

4 A. I came away with the impression that FDA
5 was going to be scrutinizing any signs and signals
6 and evaluations for liver toxicity for all
7 development compounds and probably for marketed
8 products as well.

9 Q. How did that impact your thinking about
10 what you would have to do to convince the FDA that
11 773 was safe for the liver?

12 A. I don't know that I came away from that
13 meeting with any sound or any specific conclusions
14 that there was a -- a path forward that was
15 prescribed. So, in other words, study this many
16 patients, do this, do that, and we'll consider you
17 safe.

18 It was more of an academic meeting where
19 the take-home was we don't have all the answers but
20 we're going to be looking very carefully, which
21 then, you know, convinced me that it was an issue
22 for all Abbott products under development, that we
23 would have to be very aware of and very thorough
24 with our assessment.

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 Q. Were you more or less optimistic that
2 you could achieve regulatory approval for 773 after
3 the meeting?

4 MR. PHILLIPS: Objection; assumes facts not in
5 the record.

6 BY THE WITNESS:

7 A. I don't believe I looked at that meeting
8 and its results as anything that would have
9 impacted my assessment of any of the programs that
10 we had underway.

11 BY MR. ZWICKER:

12 Q. Turn to -- on page 044, there is a
13 section that begins with "773 IV Formulation
14 Program."

15 Do you see that?

16 A. Yes.

17 Q. Turn the page. It says, "The IV
18 formulation program is presently unfunded."

19 Do you see that?

20 A. Yes.

21 Q. Did you know that, that as of
22 February 2001 that the IV program was unfunded?

23 A. I don't recall.

24 Q. Given your attendance at FDA meetings in

1 2000, did you believe that it was important for

2 Abbott to fund an IV program in connection with

3 achieving a resistance claim for 773?

4 MR. PHILLIPS: Objection; vague.

5 BY THE WITNESS:

6 A. I -- I think my impression was that

7 having the IV product would have made running the

8 IV to oral stepdown studies much more practical and

9 doable.

10 BY MR. ZWICKER:

11 Q. And in terms of achieving a resistance

12 claim, an IV program would have been a positive

13 factor?

14 A. I believe so.

15 Q. Look at the same paragraph I read you,

16 the very last bullet, it says, "Provide additional

17 information on QTc effects."

18 Do you see that?

19 A. Yes.

20 Q. Can you explain how an IV program would

21 have provided information on QTc effects?

22 MR. PHILLIPS: Objection; lack of foundation.

23 BY THE WITNESS:

24 A. No, I can't.

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 True?

2 A. Correct.

3 MR. PHILLIPS: I'm going to object that the

4 question is argumentative. You used the word

5 "though."

6 (WHEREUPON, a certain document was

7 marked Fox Deposition Exhibit

8 No. 10, for identification, as of

9 05-17-2007.)

10 MR. ZWICKER: The record should reflect that

11 before the witness is Fox Exhibit No. 10, which is

12 a series of e-mails bearing Bates No. 568172.

13 BY MR. ZWICKER:

14 Q. Ms. Fox, could you review Exhibit 10 and

15 let me know when you're done.

16 A. Okay.

17 Q. Do you recognize this document?

18 A. I don't recall the document

19 specifically, no.

20 Q. Do you recall the issue that the

21 document relates to?

22 MR. PHILLIPS: Objection; vague.

23 BY THE WITNESS:

24 A. Yes, pediatric rule requirements were a

1 Do you see that?

2 A. Yes, I see the statement.

3 Q. Do you remember an issue in February of
4 2001 at Abbott regarding failure to fund pediatric
5 programs for compounds under development?

6 A. Not specifically, I don't recall that.

7 Q. What about generally?

8 A. Generally I remember that the first
9 several years after the pediatric rule requirement
10 came into effect that -- excuse me.

11 Q. Sure.

12 A. The project teams were not used to
13 planning pediatric programs early in the process.
14 They were used to waiting until they -- they had a
15 lot of data in hand on the adult program to make
16 decisions about whether to take a given product
17 into pediatrics.

18 And, so, it was a -- it was a time where
19 we as the regulatory contributors to the project
20 teams had to keep reminding them that you now have
21 a new requirement to meet. You now have to plan
22 your pediatric programs. You have to start your
23 development of your pediatric dosage forms sooner
24 because at some point you will reach the point

1 BY MR. ZWICKER:

2 Q. During this period of time?

3 A. I believe so.

4 Q. And is it fair to say if you went to the
5 FDA seeking an NDA and didn't have your -- and
6 hadn't satisfied the pediatric rule, the FDA might
7 deny your application?

8 MR. PHILLIPS: Objection; lack of foundation,
9 calls for speculation.

10 BY THE WITNESS:

11 A. I believe that was a theoretical
12 possibility that had not been put to the test.

13 BY MR. ZWICKER:

14 Q. In your experience did it ever happen
15 that the FDA denied an NDA for failure to satisfy
16 the pediatric rule?

17 A. I don't know.

18 Q. That you can remember in your
19 experience.

20 A. In my experience in the products that I
21 worked on, not to my recollection.

22 Q. You write back, returning to the e-mail
23 now, "I share your concern and have an even bigger
24 one. In those cases where we are planning to

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 develop an NCE and we have" an NDA -- "a target NDA
2 date, I have had difficulty convincing people that
3 they have to take the pediatric rule requirements
4 seriously."

5 What's an NCE?

6 A. New chemical entity.

7 Q. Is 773 an NCE?

8 A. Yes.

9 Q. Did you have a target NDA date for 773
10 as of --

11 A. I believe we did.

12 Q. You say, "I have difficulty convincing
13 people to take the pediatric rule requirements
14 seriously."

15 Did you encounter that problem with
16 respect to 773 in 2001?

17 MR. PHILLIPS: Objection; vague.

18 BY THE WITNESS:

19 A. Based on this e-mail, I believe it
20 probably was the case.

21 BY MR. ZWICKER:

22 Q. What people did you have in mind when
23 you wrote this sentence?

24 A. Probably the project team.

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 Q. But you have no doubt since you wrote
2 this e-mail that you must have had such
3 difficulties with some persons, right?

4 MR. PHILLIPS: Objection; calls for
5 speculation.

6 BY THE WITNESS:

7 A. Since I wrote the e-mail, that was --
8 that was apparently what my thinking was at the
9 time.

10 BY MR. ZWICKER:

11 Q. The next sentence you have is, "The
12 answer I keep getting on ABT-773 is 'but that
13 project isn't funded.' I don't think the FDA will
14 buy that answer."

15 Do you recall who gave you the answer
16 that the pediatric studies for 773 aren't funded?

17 A. No.

18 Q. But you don't doubt that somebody gave
19 you that explanation based on this e-mail, right?

20 A. Based on the e-mail.

21 Q. Is it fair to say that you were
22 frustrated by the 773 development team's
23 inattention to the pediatric rule?

24 MR. PHILLIPS: Objection; mischaracterizes the

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 testimony.

2 BY THE WITNESS:

3 A. I don't recall that I would say

4 frustrated. All I -- all I have to go on is what I

5 see before me.

6 BY MR. ZWICKER:

7 Q. Well, clearly you're not happy about it,

8 right?

9 MR. PHILLIPS: Objection and calls for

10 speculation.

11 BY THE WITNESS:

12 A. I think the e-mail was a response to one

13 of my colleagues raising this as a -- as a global

14 issue and I indicated that I shared the concern.

15 BY MR. ZWICKER:

16 Q. For 773?

17 A. Specifically for 773.

18 Q. And you conclude by saying, "I don't

19 think the FDA will buy that answer."

20 Do you see that?

21 Is that your way of saying that the FDA

22 won't approve an NDA unless the pediatric rule is

23 satisfied?

24 A. No.

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 Q. What are you saying when you say "I

2 don't think the FDA will buy that answer"?

3 A. If the answer is that the project isn't

4 funded, that would not be an acceptable response to

5 a question from FDA about the -- the pediatric

6 studies.

7 Q. As of February 14, 2001, as far as you

8 knew, based on this e-mail, the pediatric program

9 wasn't funded, right?

10 MR. PHILLIPS: Objection; lack of foundation.

11 BY THE WITNESS:

12 A. I don't remember.

13 BY MR. ZWICKER:

14 Q. You write, "The answer I keep getting is

15 'but that project isn't funded.'"

16 Do you see that?

17 A. Yes, I see that.

18 Q. Does that cause you to conclude that as

19 of February 14, 2001, the pediatric program wasn't

20 funded?

21 MR. PHILLIPS: Objection; calls for

22 speculation, lack of foundation.

23 BY THE WITNESS:

24 A. It tells me that when I wrote this

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 A. Correct.

2 MR. ZWICKER: Nothing further.

3 MR. PHILLIPS: I have no further questions.

4 MR. ZWICKER: Thank you.

5 THE VIDEOGRAPHER: We are going off the video

6 record at 3:18 p.m. This concludes Tape No. 4.

7 (Time Noted: 3:18 p.m.)

8 FURTHER DEPONENT SAITH NAUGHT.

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 UNITED STATES DISTRICT COURT
2 FOR THE DISTRICT OF MASSACHUSETTS
3 JOHN HANCOCK LIFE INSURANCE)
4 COMPANY, et al.,)
5 Plaintiffs,) Civil Action No.
6 -vs-) 05-11150-DPW
7 ABBOTT LABORATORIES,)
8 Defendant.)

9
10
11 I hereby certify that I have read the
12 foregoing transcript of my deposition given at the
13 time and place aforesaid, consisting of Pages 1 to
14 183, inclusive, and I do again subscribe and make
15 oath that the same is a true, correct and complete
16 transcript of my deposition so given as aforesaid,
17 and includes changes, if any, so made by me.

18
19 JEANNE FOX
20 SUBSCRIBED AND SWORN TO
21 before me this day
22 of , A.D. 200__.

23 Notary Public

24

1 STATE OF ILLINOIS)

2) SS:

3 COUNTY OF DU PAGE)

4 I, CORINNE T. MARUT, C.S.R. No. 84-1968,

5 a Notary Public within and for the County of

6 DuPage, State of Illinois, and a Certified

7 Shorthand Reporter of said state, do hereby

8 certify:

9 That previous to the commencement of the

10 examination of the witness, the witness was duly

11 sworn to testify the whole truth concerning the

12 matters herein;

13 That the foregoing deposition transcript

14 was reported stenographically by me, was thereafter

15 reduced to typewriting under my personal direction

16 and constitutes a true record of the testimony

17 given and the proceedings had;

18 That the said deposition was taken

19 before me at the time and place specified;

20 That the reading and signing by the

21 witness of the deposition transcript was agreed

22 upon as stated herein;

23 That I am not a relative or employee or

24 attorney or counsel, nor a relative or employee of

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 such attorney or counsel for any of the parties

2 hereto, nor interested directly or indirectly in

3 the outcome of this action.

4 IN WITNESS WHEREOF, I do hereunto set my

5 hand and affix my seal of office at Chicago,

6 Illinois, this 28th day of May, 2007.

7

8

9

10 CORINNE T. MARUT, C.S.R. No. 84-1968

11 Notary Public, DuPage County, Illinois.

12 My commission expires August 15, 2009.

13

14

15

16

17

18

19

20

21

22

23

24

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 INDEX

2 JEANNE FOX EXAMINATION

3 BY MR. ZWICKER..... 5

4 BY MR. ZWICKER.....124

5 BY MR. PHILLIPS.....178

6 BY MR. ZWICKER.....180

7

8

9 EXHIBITS

10 FOX DEPOSITION EXHIBIT MARKED FOR ID

11 No. 1..... 23

12 No. 2..... 25

13 No. 3..... 47

14 No. 4..... 55

15 No. 5..... 56

16 No. 6..... 95

17 No. 7..... 97

18 No. 8.....104

19 No. 9.....126

20 No. 10.....129

21 No. 11.....139

22 No. 12.....145

23

24

Fox, Jeane [Final] 5/17/2007 9:10:00 AM

1 EXHIBITS

2 FOX DEPOSITION EXHIBIT MARKED FOR ID

3 No. 13.....147

4 No. 14.....150

5 No. 15.....154

6 No. 16.....164

7 No. 17.....168

8 No. 18.....173

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

Deposition Exhibit 2

P's Exhibit HZ



Gregory
Bosco/LAKE/PPRD/ABBOTT

09/13/2000 12:44 PM

To Carol S Meyer/LAKE/PPRD/ABBOTT@ABBOTT
cc George Ayntilan/LAKE/PPRD/ABBOTT@ABBOTT
bcc
Subject ABT-773 Dev Plan

Carol,


Here's the PPD Regulatory piece. Jeanne has reviewed it.

Greg



Development Plan - 9-00.doc

CONFIDENTIAL
ABBT0557552





Gregory
Bosco/LAKE/PPRD/ABBOTT

09/13/2000 12:44 PM

To Carol S Meyer/LAKE/PPRD/ABBOTT@ABBOTT
cc George Aynilian/LAKE/PPRD/ABBOTT@ABBOTT
bcc
Subject ABT-773 Dev Plan

Carol,


Here's the PPD Regulatory piece. Jeanne has reviewed it.

Greg



Development Plan - 9-00.doc

CONFIDENTIAL
ABBT0557552



D. Regulatory Strategy

D.1 Regulatory Strategy SWOT Analysis

Table D.1 SWOT Analysis (Strengths/Weaknesses/Opportunities/Threats)		
CATEGORY	ITEM (Probability/Impact)	STRATEGY
Strengths	<ul style="list-style-type: none"> QED dosing may be viewed as positive for patient compliance if data is strong 	Make sure PK/PD data is available to support dose selection rationale
	<ul style="list-style-type: none"> If the drug has a favorable risk benefit ratio with added value compared to existing therapies then the likelihood of approvability is high in EU countries or other countries requiring a CPMP package 	The development programs must be designed to unequivocally demonstrate the existence of an added value (e.g. safety or clinical efficacy against resistance species)
	<ul style="list-style-type: none"> ABT-773 may present a key point of differentiation with promising activity against macrolide and penicillin resistant <i>Streptococcus pneumoniae</i> and enhanced antibacterial activity <i>in vitro</i>. If proven <i>in vivo</i>, this may indicate favourable relative therapeutic value required for approval and inclusion within local use guidelines. <p>For COFs countries, if the US or EU receives approval then approvals in these LA/PAA countries are assured assuming appropriate sourcing.</p>	<p>To utilize the enhanced bacterial activity as a key point of differentiation need to:</p> <ul style="list-style-type: none"> Ensure clinical program is designed to optimize chances of obtaining desired isolates Ensure appropriate pk/pd studies are performed Seek agreement from FDA regarding burden of proof for labeled indication against resistant pathogens
Weaknesses	<ul style="list-style-type: none"> Take with food labeling is required to reduce AE's 	FDA will still require pivotal bioavailability studies to be done in fasted state.
	<ul style="list-style-type: none"> If BID is chosen for either CAP or ABS, diurnal variation may become an issue during FDA review Conformance to Abbott's & FDA's Electronic Document Management System requirements may impact filing date High COG's for bulk drug driving vendor matrix and push to redefine starting material 	<p>Justification must be provided</p> <p>Electronic filing likely to be valued very highly by FDA, so need to manage internal process to see that we can meet requirements</p> <p>Need FDA buy-in from End-of-Phase 2 CMC meeting on starting material and vendor matrix, including stability requirements</p> <p>Communicate with team, international</p>

CONFIDENTIAL
ABBT0557553

	<p>Harmonization of global clinical trial designs and guidelines</p> <ul style="list-style-type: none"> Differences in medical practice exist worldwide for antibiotics and associated infections Differences in comparator and dosing regimens Stringent EU regulatory environment with antibiotics <p>EU filing will require a harmonized labeling therefore country-specific favourable labeling cannot be pursued (as done with clarithromycin)</p> <p>Two dose scenario with a lower dose chosen for ABECB, Sinusitis and Pharyngitis with a second dose chosen for CAP may provide limited numbers to assess safety of the higher dose</p> <p>Increased resistance awareness may influence stricter requirements and trend away from lowest effective dose</p>	<p>affiliates, international experts and discuss with EU authorities through agency meetings to ensure design of trials and comparators are acceptable</p> <p>Discuss any country specific issues with authorities, international experts and affiliates. Monitor regulatory environment and competitive products.</p> <p>Discuss issue authorities at agency meeting and ensure MAA addresses this issue. May consider Phase IV studies to address this concern.</p> <p>Ensure clinical program includes relative pk/pd studies and can demonstrate clear efficacy at proposed doses. Ensure clinical program is designed to obtain resistance isolates</p>
Opportunities	<ul style="list-style-type: none"> Labeling for resistant organisms if isolates are obtained <p>Eligible for Centralised filing process which would provide EU-wide 10 year protection. May also file by Mutual Recognition procedure which more provides flexibility for non-harmonized disease practices (e.g. infectious disease/antibiotics)</p> <p>Once Daily Dosing may enhance compliance</p>	<p>Get agreement with FDA at End of Phase 2 meeting regarding number of isolates required for labeling claim</p> <p>Filing strategy to be determined based on strength of the clinical program and advice received from agencies during planned agency meetings</p>
Threats	<ul style="list-style-type: none"> QT prolongation class labeling in Warnings section of labeling <ul style="list-style-type: none"> Liver enzyme increases in Warnings section of 	<p>Get agreement with FDA at End of Phase 2 meeting regarding EKG monitoring in Phase 3 and promote theory that QT prolongation is not class related</p> <p>Ensure that non-clinical and clinical program fulfill the CPMP points to consider on QTc prolongation.</p> <p>Ensure that non-clinical and clinical</p>

CONFIDENTIAL
ABBT0557554

	<p>labeling</p> <ul style="list-style-type: none"> Possible failure of short course therapy for Pharyngitis due to more stringent Test of Cure requirement from FDA If gastrointestinal AE's are high, may affect benefit/risk assessment by FDA Could be affected by CDC push to reduce antibiotic use; reserve use of drugs effective vs resistant organisms until existing therapies have failed 	<p>program addresses potential safety labeling issues and MAA/NDA addresses these concerns.</p>
--	--	---

D.2 Registration Strategy and Timelines for Filing

Table D.2 Registration Strategy and Timelines for Submission		
REGION	Proposed Submission Date	Justification
US	<ul style="list-style-type: none"> August 2002 	Estimated completion of the clinical program and CMC stability data
<p>Europe</p> <p>Filing procedure (Centralised or MRP) to be determined based on strength of clinical data and discussion with authorities</p>	August 2002	Estimated completion of the chemistry/pharmacy and clinical data
<p>Japan</p> <p>Plan to bridge to US data assuming pk profile is similar in Japanese subjects and a successful Phase II bridging study is possible in Japan</p>	TBD	Bridging obviates the need for a lengthy and expensive Japanese Phase III program. Requires Kiku agreement.

CONFIDENTIAL
ABBT0557555

D.3 Data Requirements and Impact on CMC/Non-Clinical/Clinical Program

Table D.3 Data Requirements and Impact on CMC/Non-Clinical/Clinical Program				
COUNTRY	Guideline Requirement	Probability of Achieving	Impact on Filing	Impact on Approvability
US	• Draft Anti-Infective Guidances for CAP, ABECB, ABS & Pharyngitis	High	High	High
	• Draft Anti-Infective Guidances – General Considerations for Clinical Trials	High	High	High
	• Anti-Infective Points to Consider document	High	High	High
	• ICH Efficacy Guidances – E1 through E12	High	High	High
	• ICH Safety Guidances – S1 through S7	High	High	High
	• ICH Quality Guidances – Q1 through Q7	High	High	High
	• ICH Quality Guidances – Q1 through Q7	High	High	High
Europe	All ICH guidelines as above, plus CPMP points to consider on QT prolongation CPMP guideline on the clinical evaluation of antibacterials DRAFT CPMP guideline for pk/pd	High/Moderate	High	High
Japan	All ICH guidelines as above plus local guidelines/JP issues, ICH E5 ethnic bridging guideline.	Moderate/Unknown	High	High

CONFIDENTIAL
ABBT0557556


D.4 Table of Proposed Discussions with Health Authorities

Table D.4 Table of Proposed Discussions with Health Authorities		
COUNTRY	Reason for Discussion	Proposed timing for Discussion
US	<ul style="list-style-type: none"> • End of Phase 2 -- Clinical • End of Phase 2 -- CMC • Pre-NDA -- Clinical • Pre-NDA -- CMC 	10/20/00 TBD TBD TBD
Europe	<ul style="list-style-type: none"> • Individual agency meetings with UK, Germany, France and Spain to discuss Phase III Clinical program trial designs • Pre-filing meetings to be determined based on filing strategy 	UK complete -- 07/10/00 Germany complete- 07/21/00 France scheduled -- 08/30/00 Spain -- to be determined
Japan	<ul style="list-style-type: none"> • KIKO- discuss bridging strategy to 300 mg EU/US program • KIKO -- re-discuss dose justification 	Complete -- June 2000 TBD

CONFIDENTIAL
 ABBT0557557

Deposition Exhibit 3

P's Exhibit ID



To: John M Leonard/LAKE/PPRD/ABBOTT@ABBOTT, Jerald J Wenker/LAKE/PPD/ABBOTT@ABBOTT, Lawrence E Roebel/LAKE/PPRD/ABBOTT@ABBOTT
Arthur J Higgins/LAKE/PPD/ABBOTT@ABBOTT, Carl Craft/LAKE/PPRD/ABBOTT@ABBOTT, George Aynilian/LAKE/PPRD/ABBOTT@ABBOTT, Reid Patterson/LAKE/PPRD/ABBOTT@ABBOTT, Julia Y Hui/LAKE/PPRD/ABBOTT@ABBOTT, William M Bracken/LAKE/PPRD/ABBOTT@ABBOTT, Maria M Paris/LAKE/PPRD/ABBOTT@ABBOTT, Joaquin M Valdes/LAKE/PPRD/ABBOTT@ABBOTT, David D

cc: Morris/LAKE/PPRD/ABBOTT@ABBOTT, Jie X Zhang/LAKE/PPRD/ABBOTT@ABBOTT, Carol S Meyer/LAKE/PPRD/ABBOTT@ABBOTT, Robert K Flamm/LAKE/PPRD/ABBOTT@ABBOTT, Linda E Gustavson/LAKE/PPRD/ABBOTT@ABBOTT, Gregory Bosco/LAKE/PPRD/ABBOTT@ABBOTT, Rod M Mittag/LAKE/PPD/ABBOTT@ABBOTT, Linda J Swanson/LAKE/PPRD/ABBOTT@ABBOTT, Cheryl D Spencer/LAKE/PPRD/ABBOTT@ABBOTT

bcc:

Subject: FDA Telephone Contact Report ABT-773


Attached is a contact report for a teleconference that was held with FDA today concerning ABT-773. We are now officially on clinical hold until further discussion at the End-of-Phase 2 meeting scheduled for November 27, 2000.

Call me if you have questions,

jeanne



FDA Contact Reportdoc.doc



CONFIDENTIAL
ABBT0558681

FDA Contact Report

Compound/Product Discussed: ABT-773
 Application Type & Number: IND 57,836

Date of Contact: November 20, 2000

	Name & Title	Group
FDA Person(s) Contacted	Dr. Janice Soreth, Acting Division Director	Division of Anti-Infective Drug Products
	Dr. Mercedes Albuerno, Supervisory Medical Officer	
	Dr. Alma Davidson, Medical Officer	
	Dr. Bob Osterberg, Supervisory Pharm/Tox Reviewer	
	Dr. Terry Peters, Pharm/Tox Reviewer	
	Maurcen Dillon-Parker, CSO	
	Jeanne Fox	Regulatory Affairs
Abbott Representatives	Greg Bosco	"
	Carl Craft	Venture
	George Aynilian	"
	Reid Patterson	Drug Safety
	Bill Bracken	"
	Julia Hui	"

Subject of Call: FDA requested this teleconference to talk about some "toxicology issues" prior to our End-of-Phase 2 meeting scheduled for next week (November 27, 2000).

Report of Call: The meeting began with introductions, then Maurcen said she was filling in for our CSO, Jose Cintron, and asked if we had been told the subject of the call. I told her we understood the purpose to be tox, but had no specifics. Dr. Peters then began by saying that she reviewed our 3 month monkey toxicology study as well as the inspection report and has several concerns about the study. First, there is a concern because the FDA investigator found that there was active drug in some of the control samples. Second, they have knowledge which they cannot share with us regarding similar drugs that has convinced them that the monkey is not a sensitive enough species to look for the two primary toxicities they are worried about with macrolides and ketolides, hepatotoxicity and QT changes. They had advised us of their recommendation that we use the dog after the results of the one month monkey tox study, and now they are looking at a 3 month study in monkeys that they believe is flawed. Reid explained the rationale behind not using the dog since our early work in dogs indicated that emesis became so pronounced in dogs that we were unable to reach significant drug exposures, therefore we switched to monkeys. They asked whether we had done QT assessment in this study and we responded no, that our QT evaluation was done by the safety pharmacology group. They responded that they were looking for QT assessment on multiple dosing in toxicology studies, not the kind of information that came out of single dose pharmacology studies. They then stated that to meet the requirement to start phase 3, they need chronic toxicology done in two species and so they want us to do a 30-day dog study with full QT assessment done by telemetry and evaluation for hepatotoxicity. I pointed out that we have provided in our pre-meeting package specific analyses of both our hepatic safety evaluations and our QT monitoring results from the 900 plus patients that we have treated in Phase 1 and 2. Reid stated that since nothing significant was seen in any of the human data it would seem somewhat meaningless to go back and do the dog study. FDA asked to put us on hold.

When they came back after 5 minutes they said they would propose a compromise, and instead of a 30 day study, they would require a two week dog study with special emphasis on hepatotoxicity and QT, with telemetry and with a

CONFIDENTIAL
 ABBT0558682

recovery period. We agreed that it may be possible to run such a study, although we still have concerns about getting adequate exposures in the dog. I then said that our bigger concern was allowing this tox request to delay our phase 3 studies, and asked if it would be acceptable to run the tox study concurrently since the Phase 3 studies had already started. Based on FDA's reaction it was clear they were unaware that we have begun our studies. Dr. Soreth asked how we could do that prior to our end-of-phase 2 meeting. I pointed out that we had first requested a meeting in July, and it has been scheduled and rescheduled several times. I referenced the letter I sent to her in October when they cancelled the scheduled meeting the last time, which told her we would begin our trials the second week in November. I also referred to the new protocol amendments that were submitted over the last several weeks initiating the studies. She said they expected us to send the protocols to them and wait for comments before proceeding. I explained that we have received comments on at least one of the protocols and parts of the others. She wanted to know if our recent submissions stated we were planning to enroll patients now. I responded that these are our standard study start-up submissions that include information on a minimum of one investigator who can then enroll patients. I explained that we have several patients currently enrolled. Dr. Soreth was not happy with this information, and FDA put us on hold again.

When FDA came back off hold Dr. Soreth told us that they were not expecting us to begin our phase 3 studies prior to the end-of-phase 2 meeting, and that they want us to suspend enrollment at this time. In other words, we are now on clinical hold with these studies. They will discuss this information further prior to the meeting next Monday. I asked whether the 1 hour that has been allotted us next Monday will be enough. Dr. Soreth responded that it will have to be. She indicated they are probably still going to require a dog study. I commented that we do have in writing from Dr. Peters that the three-month study in monkeys should be acceptable to fulfill the requirement. We received this in response to our argument against using dog when they first raised it last year. They did not have the reviewers document in front of them, and Dr. Peters could not recall it, so they said they would go back and look through their records. She also stated that regardless, they would still have issues with the quality of the 3 month study. Reid promised to provide a written response to the issue of active drug in control samples, stated again that there was nothing significant enough to invalidate the study, and questioned whether we could get the exposures they were looking for in dogs. Dr. Peters commented that other sponsors with drugs like these manage to do dog studies. We agreed to provide an estimated timeline for a two-week dog study at Monday's meeting.

We suggested to Dr. Soreth that they also review the QT and hepatic safety assessments that were done in phase 2 since those were done at doses up to 600 mg, so there is more exposure in those phase 2 studies than we will have in phase 3. She said they will look at it.

Action Items: Provide a chronology showing all of the delays in getting the phase 2 meeting to happen as well as the submission of the protocols for review and the response from Dr. Peters acknowledging the 3 month monkey study as acceptable. Prepare a written response regarding the positive study drug in controls from the 3 month tox study.

CONFIDENTIAL
ABBT0558683

Deposition Exhibit 4

P's Exhibit IG



Jeanne M
Fox/LAKE/PPRD/ABBOTT
11/29/2000 01:48 PM

To: Rod M Mitleg/LAKE/PPD/ABBOTT@ABBOTT, Carl
Craik/LAKE/PPRD/ABBOTT@ABBOTT, George
Aynsian/LAKE/PPRD/ABBOTT@ABBOTT
cc: Lawrence E Roebel/LAKE/PPRD/ABBOTT@ABBOTT,
Gregory Bosco/LAKE/PPRD/ABBOTT@ABBOTT
bcc:
Subject: Slides for 12/5 meeting


OK, here's my first draft of slides for the Leiden meeting. Please feel free to make comments or redirect me if you think I'm missing something. I guess I think after our meeting on Monday, the only major issues identified which are still open are QT, liver, and resistant pathogens, so that's what I focussed on with some general comments at the end.

Jeanne

p.s I apologize for the separate files. I am obviously not as good on my PC as Rod is



Leidenslides1.ppt Leidenslides2.ppt Leidenslides3.ppt Leidenslides4.ppt Leidenslides5.ppt Leidenslides6.ppt



CONFIDENTIAL
ABBT0556816

ABT-773 Regulatory Status

- Original U.S. Oral IND submitted 2/2/99
- Phase 3 pivotal trials initiated 11/00
- End-of-Phase 2 Clinical FDA meeting
11/27/00
- End-of-Phase 2 CMC FDA meeting target
1/01
- Tablet NDA submission target 8/02

ABT-773 Regulatory Issues

- ABT-773 Potential for QT Prolongation
 - QT issue is hot button for FDA
 - Question whether ketolides behave like macrolides
 - FDA requested additional dog tox work to evaluate QT
 - Required to include ECG monitoring in pivotal Phase 3 studies

ABT-773 Regulatory Issues

- ABT-773 Potential for QT Prolongation (continued)
 - telithromycin (Ketek) data residing at FDA
 - Advisory Meeting scheduled for January
- FDA may require a Phase 1 study in patients with underlying cardiac disease
- Some antimicrobials now contain warnings for QT prolongation

ABT-773 Regulatory Issues

- **ABT-773 Potential for Liver Toxicity**
 - Ketolides similar to macrolides?
 - Request for additional dog tox work
 - telithromycin (Ketek) data residing at FDA
 - Advisory meeting scheduled for January
- **Plan to conduct routine liver monitoring in all Phase 3 studies**

I

CONFIDENTIAL
ABBT0556820

ABT-773 Regulatory Issues

- Indication to treat resistant pathogens
- FDA skepticism regarding clinical significance of "macrolide-resistant *S. pneumo*"
- FDA will require "body of evidence"
 - excellent eradication of susceptible organisms
 - > 10 resistant organisms eradicated to include good proportion of bacteremic CAP patients

ABT-773 Regulatory Issues

- Miscellaneous
 - Based on NDA timing, potential good candidate for E-submission
 - Timing of IV program may affect ability to document effectiveness vs. resistant pathogens in bacteremic patients
 - Timing of pediatric program and “due diligence” for formulation development critical

Deposition Exhibit 5

P's Exhibit IE

FDA Contact Report

Compound/Product Discussed: ABT-773 - End of Phase 2 Meeting

Application Type & Number: IND 57,836

Date of Contact: November 27, 2000

	Name & Title	Group
FDA Person(s) Contacted	Jose Cintron, Sr. Project Mgr	Anti Infective Division
	Mercedes Albuerno, Medical Team Leader	"
	Nasim Moledina, Medical Officer	"
	Mamodikoe Makhene, Medical Officer	"
	Alma Davidson, Medical Officer	"
	Daphne Lin, Statistics Team Leader	"
	Erica Brittain, M.D., Statistics Reviewer	"
	Terry Peters, Pharm/Tox Reviewer	"
	Robert Osterberg, Pharm/Tox Team Leader	"
	Lilian Gavrilovich, Deputy Director	"
	Charles Bonapace, Biopharm Reviewer	"
	Frank Pelsor, Biopharm Team Leader	"
	Sousan Altaie, Micro Reviewer	"
	Jean Mulinde, Medical Officer	"
	Jim Timper, Chemistry Reviewer	"
	Charles Cooper, Medical Officer	"
	Albert Sheldon, Micro Team Leader	"
	Janice Soreth, Acting Division Director	"
	John Alexander, Medical Officer	"
	Diane Murphy, Office Director	Office of Drug Evaluation - IV
Abbott Representative(s)	Greg Bosco, Sr. Product Mgr	Regulatory Affairs
	Jeanne Fox, Director	Regulatory Affairs
	Jie Zhang, Statistician	Clinical Statistics
	Josquin Valdes, Physician	Anti Infective Venture
	Carol Meyer, Operations Manager	Anti Infective Venture
	Bob Flamm, Microbiologist	Microbiology
	Linda Gustavson, Pharmacokineticist	Clinical Pharmacokinetics
	David Morris, Statistician	Clinical Statistics
	Maria Paris, Physician	Anti Infective Venture
	George Aynilian, Associate Venture Head	Anti Infective Venture
	Carl Craft, Venture Head	Anti Infective Venture
	John Leonard, Vice President	Research & Development
	Reid Patterson, Vice President	Drug Safety

Subject of Meeting:


The purpose of the meeting was to introduce the oral tablet Phase 3 development plan, discuss potential issues, and address any questions regarding the plan or Phase 2 study results.

Report of Meeting:

The meeting began with introductions from both sides. As Carl began his presentation, Dr. Soreth stated that in case there was some misconception regarding the result of the telecon held on 11/20/00, she wanted to say that the ABT-773 program was at this point not on clinical hold.

Confidential

ABBT205257



Carl began his presentation with a slide showing the proposed indications and treatment durations we were planning to file in the NDA. He showed a series of slides which summarized all the Phase 3 studies we are planning; those starting in 2000 and those slated for 2001. This was the first time FDA saw the proposed dose-selection studies for pneumonia (CAP) and sinusitis (ABS). Dr. Britain had a few questions regarding the objectives of the studies and the proposed interim analyses, but stated that she would be faxing us all of her comments in more detail. Carl stated that the objectives of the studies were: to pick a dose for the large, well-controlled, comparative, pivotal studies to be conducted in 2001, and to meet the specific pathogen criteria as required for the second supportive trials in the FDA guidance for CAP and ABS. There was lengthy discussion around these study designs. It was stressed to FDA that we still intend to conduct a large, well-controlled, double-blind, comparative trial for each of these indications. FDA advised us there might be a problem using Augmentin 875 mg BID for the sinusitis trial. They would prefer us to use 500 mg TID. Carl committed that we would provide the results from these two trials to FDA for review.

The next slide shown detailed our intention to request a claim for macrolide and penicillin resistant bacteria and atypical bacteria, and the supporting data we proposed to provide to support these claims. Dr. Albuerno stated that we could pool isolates for CAP and ABECB but not for ABS (we proposed pooling from all three). Dr. Soreth stated that there is currently no guidance document available addressing specific requirements for resistant claims but mentioned that there is data from other products (e.g. levofloxacin) that is available in the public domain. As far as our proposal for number of isolates, numbers >10 would be acceptable with good data for susceptible pathogens, but there has been an instance (with linezolid) where <10 was not approvable, but in that case only one or two patients had bacteremia and responded well to therapy. It was stated that a number of bacteremic patients would be required in order to adequately evaluate clinical success against penicillin resistant *Strep pneumoniae*. The comment was made that with oral therapy alone we would probably be hard pressed to find enough patients with bacteremia, that oral/IV therapy gave us a better chance. Dr. Soreth stated that FDA has not seen data supporting "macrolide resistant *Strep pneumoniae*" as a clinical concern. They also said that there is no good body of evidence supporting macrolide resistant *Strep pyogenes* either.

The next topic discussed was the ECG monitoring plan regarding the six Phase 3 studies starting in 2000. We proposed that ECG's would be performed in 5/6 of the studies. In total, we would be gathering ECG data on ~2000 subjects exposed to ABT-773. ECG's will be performed pre-, during, and post-therapy. Additionally, the timing of the ECG and the timing of the dose before the ECG will be documented. FDA requested that we amend all informed consents to mention possible effects on cardiac repolarization caused by ABT-773. Various examples of wording was then discussed and we agreed that we would amend the informed consents for all IND studies. Dr. Soreth asked why we were not doing ECG's in the sixth study. Carl stated that the European pharyngitis study would not include ECG's based on recommendations of our European advisors based on the number of existing visits and the likelihood of subject reluctance to participate in a trial for this disease with so many visits. FDA strongly disagreed with this justification. Dr. Murphy expressed concern that we were blatantly misinforming the subjects in that trial by not including a procedure that would monitor a potentially serious adverse event that was being included in all other studies. This issue was left unresolved. Other comments regarding the collection of a blood sample taken at the on-therapy ECG, etc. were made. All issues were addressed in a subsequent written correspondence by FDA (faxed 12/5/00, Abbott response 12/14/00).

Relating to the topic of possible adverse effects on cardiac repolarization, the results of the previously submitted toxicology studies were discussed. Dr. Peters requested additional data in the dog model. The requested study should be a two-week acute study with telemetry and the study can run concurrent with the Phase 3 clinical trials. At this point Reid offered to provide some background information. He indicated that the emetic activity of ABT-773 in the unanesthetized dog limits exposure in this species, leading to our selection of the cynomolgus monkey as the non-rodent model. While the primate did not indicate a risk for QTc prolongation, exposures of 17 times the human C_{max} in anesthetized dogs did lead to some prolongation. Owing to differences in protein binding, the dog receives about 3 times the amount of unbound drug than does the human with identical exposures, perhaps expanding our margin of safety. Various proposals for the study were discussed between Reid and Drs. Peters and Osterberg. We committed to sending draft protocols to Dr. Peters for review.

Carl briefly discussed the Phase 2 ECG data. Dr. Soreth informed us that they have begun to ask for special population studies with drugs that show an effect on ECG's. In this case they would be looking at a study in otherwise healthy subjects with underlying cardiovascular disease. She commented that only looking at the effects

of ABT-773 in comparator trials might not be realistic (i.e., cispripide and terfenadine looked safe in the clinic too). Dr. Murphy commented that it is in both of our best interests to get all the information we can to show how to use the drug safely.

The rest of the meeting was spent answering specific questions regarding the four main Phase 3 trials (CAP, ABS, ABECB & pharyngitis). Most of the comments related to minor protocol changes. All of the issues discussed were subsequently provided to Abbott by fax on 12/5/00. Abbott formally responded to the fax in IND 57,836, Serial No. 066, dated 12/14/00.

Action Items:

- Amend Phase 3 informed consents to incorporate statements relating to: possible effects on cardiac repolarization caused by ABT-773, possible interactions with other drugs, and stronger precautions for women of childbearing potential.
- Provide full narratives from Phase 2 studies of all patients who had an adverse event of syncope or elevated liver enzymes.
- Submit draft toxicology protocol(s) for comment prior to initiating the studies.
- Submit results from CAP and ABS dose-selection trials when available.
- Submit draft protocols for the two well-controlled, comparative, pivotal studies for CAP and ABS (to be conducted in 2001) for comment as soon as available.

Deposition Exhibit 6

P's Exhibit IF



Jeanne M
Fox/LAKE/PPRD/ABBOTT
11/28/2000 09:27 AM

To Lawrence E Roebe/LAKE/PPRD/ABBOTT@ABBOTT,
Jerald J Wenker/LAKE/PPD/ABBOTT@ABBOTT,
Rosemarie K Waleska/LAKE/PPD/ABBOTT@ABBOTT, Rod
M Mittag/LAKE/PPD/ABBOTT@ABBOTT, Arthur J
Higgins/LAKE/PPD/ABBOTT@ABBOTT, Linda J
Swanson/LAKE/PPRD/ABBOTT@ABBOTT, Mike
Rubison/LAKE/PPRD/ABBOTT@ABBOTT, Walid
Awni/LAKE/PPRD/ABBOTT@ABBOTT
John M Leonard/LAKE/PPRD/ABBOTT@ABBOTT, Carl
Craft/LAKE/PPRD/ABBOTT@ABBOTT, George
Aynilian/LAKE/PPRD/ABBOTT@ABBOTT, Reid
Patterson/LAKE/PPRD/ABBOTT@ABBOTT, David D
Morris/LAKE/PPRD/ABBOTT@ABBOTT, Jie X
cc Zhang/LAKE/PPRD/ABBOTT@ABBOTT, Linda E
Gustavson/LAKE/PPRD/ABBOTT@ABBOTT, Joaquin M
Valdes/LAKE/PPRD/ABBOTT@ABBOTT, Maria M
Paris/LAKE/PPRD/ABBOTT@ABBOTT, Carol S
Meyer/LAKE/PPRD/ABBOTT@ABBOTT, Gregory
Bosco/LAKE/PPRD/ABBOTT@ABBOTT


bcc

Subject Executive Summary of ABT-773 End-of-Phase 2 Mtg w/
FDA

Yesterday (11/27) the Abbott people on the CC list met with FDA's Anti-Infective Division for the End-of-Phase 2 meeting on ABT-773. Prior to the meeting we had been placed on clinical hold in a teleconference last Monday (11/20). Following are the high points from yesterday's meeting. Detailed minutes of the meeting will be distributed at a later time.

The meeting was generally successful. FDA stated that we are no longer on clinical hold and may proceed with our Phase 3 trials. They have requested additional toxicology work be done to evaluate QT in dogs, but the study can be done concurrently with Phase 3 and they will consider study design proposals from Abbott. FDA accepted the design for the CAP and sinusitis dose-selection studies, although they suggested changes to the statistical analyses for these studies. While FDA acknowledged that our proposal for 15 resistant isolates/pathogen to support a claim for resistant organisms looked reasonable, they will need a good, solid body of evidence. They cautioned us that they have not seen a body of data that supports macrolide resistant Strep pneumo as a clinical concern. They also advised us that we would need to include bacteremic CAP patients with resistant pathogens in order to secure an indication, which would be difficult to do with an oral drug. The FDA reviewers provided a number of recommended protocol changes, most of which are minor to actual study conduct. In addition, we were directed to modify all of our informed consents to inform patients that QT prolongation has been seen with related classes of drugs and therefore may be a risk with ABT-773.

jeanne



CONFIDENTIAL
ABBT0558150

Deposition Exhibit 8

P's Exhibit IO

ABT-773 Update February 12, 2001**Introduction**

ABT-773 is a ketolide antimicrobial, an evolutionary step from the macrolide antimicrobials such as erythromycin and the new generation macrolides like clarithromycin and azithromycin. It is in phase III development as a replacement to clarithromycin.

The antibiotic market is a large market (\$20.5 Billion in 1999) and is expected to expand on a global sales basis (\$26.5 Billion in 2005). The majority of the markets sales are in the oral tablet/capsule segment. Market sales increases are being driven by replacement of older/cheaper agents with branded agents. Zithromax has driven market demand for cost/convenience/tolerability, while the quinolones (Levaquin, Tequin, Avelox) are the fastest growing segment, playing into resistance concerns. Resistance is a major driving force for both the quinolones and ketolides development.

Ketolides are a Novel Class of Antimicrobial


- Active includes key respiratory tract infection pathogens including macrolide and penicillin resistant *S. pneumoniae* and *S. pyogenes*
- Bactericidal activity
- Prolonged post antibiotic effect
- Reduced resistance development

ABT-773 is the most active ketolide presently under development. It is 5 to 10 times more active than telithromycin (Aventis ketolide) against *S. pneumoniae* and *S. pyogenes* including resistant strains. It has equal activity to telithromycin and azithromycin against *H. influenzae*. The increased activity can be attributed to increased ribosomal binding. Compared to macrolides that bind only to domain V, ABT-773 binds to both domains II and V. The binding is essentially irreversible and provides bactericidal activity against *S. pneumoniae*.

Key issues facing the ABT-773 development program are summarized below**QTc Issues**

The potential for QTc prolongation is currently a prominent issue facing drug development across therapeutic areas-worldwide. Antimicrobial agents including macrolides and quinolones are of concern to regulatory agencies. There is considerable scientific uncertainty in relating the findings from in vitro assays and animal models to clinical risk of malignant arrhythmias. In an effort to gain more

onfidential



ABBT205042

knowledge these agencies are requiring the pharmaceutical companies to do additional test including

- ICH guidelines require data from animal models and 200 patients
- FDA is in the process of evaluating all drug class known to have a potential for prolonging QTc (erythromycin and clarithromycin)
- FDA has question whether ketolides behave like macrolides
- FDA requested additional dog tox work to evaluate QTc of ABT-773
- ABT-773 studies required including ECG monitoring in pivotal Phase 3 studies.
- FDA may require a Phase I study in patients with underlying cardiac disease, but the design for these studies has not been determined.
- Some antimicrobials now contain warnings for QT prolongation such as moxifloxacin.
- Telithromycin (Ketek) data residing at FDA will be reviewed by FDA Advisory Committee at a meeting scheduled for May 2001 probably related to concerns about efficacy and not related to QTc concerns.

The ketolide ABT-773 will be considered guilty until proven innocent because it is related to erythromycin and clarithromycin which are also suspect and under scrutiny. ABT-773 has the following data related to its potential or lack of potential to affect the QT interval.

- Preclinical data positive for QTc dose response.
- A possible dose effect in Phase I at total daily dose ≥ 800 mg.
- No significant QT effect observed when ABT-773 was administered with the metabolic inhibitor ketoconazole. (Increased ABT-773 Cmax 5X)
- No concentration response in Phase I studies (≤ 300 mg).
- No consistent QT effect observed at clinical doses studied in Phase IIB studies. (150 mg QD to 600 mg QD)

The Venture plan for dealing with the uncertainties related to developing a drug which has an unknown potential for prolonging the QT intervals is to pro-actively attempt to find out as much about our drug and the science related to QTc by;

- Completed preclinical evaluation of ABT-773
- Initiate FDA recommended dog studies.
- Completed ECG monitoring of >200 patients in Phase II and III
- Continue to monitor QTc and electrolytes in Phase III programs.
- Perform FDA requested study of QTc in patients with pre-existing cardiac disease; perform phase I study as required by CPMP.
- IV ABT-773 Phase I study will monitor QTc carefully
- Consult with Drs. Morganroth and Moss QTc advisors.

Liver Toxicity Issues

The FDA has similar concerns regarding the potential for liver toxicity of new drugs as it has for QTc issues, since both of these problems have resulted in

drugs being removed from the market shortly after approval. The concerns have been directed at the quinolones, but all antimicrobials are under going extensive evaluations. The FDA has a meeting on guidance to industry on how to study the potential for liver toxicity, scheduled for February 11-12, 2001. Jean Fox will attend this meeting and report back on it so that we will be able to update this topic at the February meeting.

In the Japanese bridging study run in Hawaii we saw increases in LFTs in Japanese subjects. This was very disturbing, since increases in LFTs were seen only in the Japanese subjects. In addition the Japanese subjects had AUCs which were 50% higher than the western subjects. LFTs in over 1000 western subjects did not show any problems. Since, the Japanese subjects with elevated LFTs did not show a dose response, it was felt that the changes in LFTs might be related to the high caloric diet on the unit. To answer this question Phase I food interaction and a repeat of the bridging study was preformed in Japan. The results of this study showed no evidence of any problem with LFTs in the Japanese or Caucasians. Based on the encouraging results we will continue moving forward with the Japan Program.

Phase III Tablet Program

The Phase III tablet program is underway after several delays related to manufacturing of the 150 mg tablet to replace the 300 mg tablets and the late date (11/27/00) of the FDA End of Phase II meeting. The present plan is to complete the Phase III 150 mg once daily indications in the US and Europe this year. These studies include two pharyngitis studies compared to penicillin 500 mg TID, one ABECB study in the US compared to Azithromycin, and one European ABECB study compared to Levofloxacin. The CAP and sinusitis dose selections studies are running globally, but no European sites are enrolling yet due to the changes in the protocol following the FDA End of Phase II meeting. We are increasing sites and planning to go to the Southern Hemisphere if needed to complete the studies before the start of the fall respiratory season. These changes have added additional costs that will add approximately \$5.0 MM to the budget.

The results of the CAP and Sinusitis studies have the potential of generating divergent development paths based on differences in AI and PPD regulatory and commercial considerations. PPD would prefer to have 150 mg once daily for all indications and AI would prefer 150 mg once daily for pharyngitis and ABECB and 150 mg BID for CAP and sinusitis. Once we complete the study we will need to meet to iron out the possible options.

ABT-773 IV Formulation Program

The IV formulation program is presently unfunded. The IV program is important to overall program because of the following;

- Hospital formulary acceptance
- XX% share gain in Tab sales due to step-down therapy
- Positions 773 for serious infections
- Support for *S. pneumoniae* resistance claim
 - FDA indicated that bacteremic patients will be important to establish body of evidence for this claim
- Provide additional information on QTc effects

The ABT-773 IV program received partial funding last year both from PPD and HPD, but has not been funded for 2001. The following outlines the IV program fund and funding needed.

- PPD/HPD Collaboration initiated 9/99
- PPD funded Program 01/00-08/00 (\$1.4MM)
 - Formulation development (lactate salt, lyophilized powder)
 - Animal pain models
 - Two week Tox study (monkey)
- HPD funded Program 08/00-12/00 (\$0.8MM)
 - Two week Tox study (rat)
 - Clinical supplies for Phase I
 - Stability program
- 2001 funding
 - HPD first pass funding cut for 773 IV (\$7MM)
 - Milestone funding to Phase I Go/No Go (\$1MM)
- Total program development costs 2000 - 2003 (\$22.5MM)

The clinical program with 2001 funding decision in February will included;

- | | |
|--|---------|
| • Single Dose-rising Phase I study | Apr/01 |
| • Multiple Dose Phase I with selected dose | June/01 |
| • File US IND | Oct/01 |
| • Initiate Phase III | Dec/01 |
| – 2 step-down CAP studies (US/Europe) | |
| – 2-3 days dosing | |
| – Two seasons to complete | |
| • Filing | Aug/03 |

The Venture would recommend funding the Phase I study to determine safety and tolerability profile as a GO/No Go decision. Assuming a GO decision we would need \$7 MM 2001 to start Phase III program.

Pediatric Program

The pediatric suspension program is on hold. ABT-773 is 5 to 7 times more bitter than clarithromycin. This will make the development of an acceptable formulation very difficult. The first prototype tested had a taste that was better than clarithromycin but not as good as azithromycin. The pharmacokinetics showed AUCs that were only 70% of the tablet formulation. Even with the difficulties of making an acceptable formulation the pediatric formulation would have benefits including increasing the perception of safety, better pricing and acceptance in European markets, and FDA requires studies in pediatrics. The Venture would recommend continuing the hold until we resolve other issues and then re-evaluate possible ways of overcoming the taste problem.

Japan Development Program

The Japan development program is planned in coordination with Taisho and Dainabot. Taisho funds 10.69% of global development costs and 50% of local Japan costs. The Venture is attempting to use a bridging strategy as the primary plan for development in Japan. The Phase I studies in Japan which were initiated in response to the LFT problems in the first bridging study, have been completed. There were not increases in the LFTs of the Japanese or Caucasians in the study. We will be meeting with Taisho and Dainabot to formulate a plan to present to Kiko in the 2nd or 3rd Quarter.

Deposition Exhibit 10

P's Exhibit IQ



Jeanne M
Fox/LAKE/PPRD/ABBOTT
02/14/2001 01:04 PM

To: James Steck/LAKE/PPRD/ABBOTT@ABBOTT
cc: Lawrence E Roebel/LAKE/PPRD/ABBOTT@ABBOTT
Subject: Re: Studies to Meet Pediatric Rule Requirements

I share your concern and have an even bigger one. In those cases where we are planning to develop an NCE, and we have a target NDA date, I have had difficulty convincing people they have to take the pediatric rule requirements seriously. The answer I keep getting on ABT-773 is "but that project isn't funded". I don't think FDA will buy that answer.
James Steck




James Steck
02/05/2001 05:20 PM

To: Jeanne M Fox/LAKE/PPRD/ABBOTT@ABBOTT, Lawrence E Roebel/LAKE/PPRD/ABBOTT@ABBOTT
cc:
Subject: Studies to Meet Pediatric Rule Requirements

Jeanne and Mick

This is just a heads up to let you know that there may be some issues arising in the future about concerns for being able to do studies requested by FDA to meet pediatric rule requirements because these studies "are not funded". Steve and I are running into discussions on this for Depakote ER in migraine where FDA has asked us to do an efficacy study in migraine per the pediatric rule. Of course we will attempt to negotiate with FDA to do the least onerous studies that will still satisfy the pediatric rule requirements, but folks will need to be advised at some point (preferably early on) that meeting this rule is a regulatory obligation and a cost of doing business. I'd appreciate hearing any thoughts you have on this subject.

Jim



CONFIDENTIAL
ABBT0568172